top of page

Cambridge, UK based Mestag Therapeutics last month announced a license and research collaboration with MSD to leverage the company's fibroblast platform to find inflammatory disease targets

  • Nov 14, 2024
  • 1 min read

CEO Susan Hill describes the role that fibroblasts play in regulating immune responses to inflammatory conditions and how Mestag is leveraging this in drug development. It now has the partnership with MSD, as well as a prior one with Janssen, and it's own assets in oncology and autoimmune disease.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page